Shingrix Effectiveness in Preventing Shingles in Seniors
A real-world analysis reveals that Shingrix is highly effective in preventing shingles in adults over 65, including those with compromised immune systems.
Shingles, a viral infection caused by the reactivation of the varicella-zoster virus (VZV), is more common in adults over 50, according to the CDC. It manifests as a painful rash with blisters across the chest, abdomen, or face.
Key findings include:
- Two doses of Shingrix provide better protection than one.
- Shingrix is effective in preventing shingles in immunocompromised adults.
- Between 5% and 30% of patients with shingles experience post-herpetic neuralgia (PHN), a long-lasting nerve pain.
Shingrix is a recombinant zoster vaccine (RZV) manufactured by GSK.
Author's summary: Shingrix prevents shingles in seniors.